



1/13

**FIG. 1: XRPD diffractogram of 6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide Form B**




2/13

FIG. 2: DSC trace of 6-fluoro-5-[4-[[5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide  
Form B




3/13

FIG. 3 : XRPD diffractogram of 6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide Form D




4/13

**FIG. 4:** Single crystal structure of 6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide -Form D (ORTEP50)



5/13

**FIG. 5: XRPD diffractogram of 6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide MSA salt Form C**



6/13

FIG. 6: DSC trace of 6-fluoro-5-[4-[[5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide MSA salt Form C




FIG. 7: Cell confluence graphs representing the potent PARP inhibitor monotherapy activity in glioma cells with ATRX mutation (SJG2IDH1m and SJG2IDH1wt) but not wild type ATRX (U87 IDH1wt and U87 IDH1mt)




FIG. 8: Cell confluence graphs representing PARP inhibitor potentiation of TMZ efficacy in U87 IDH1wt (A) and U87 IDH1mt R132H (B) isogenic pairs. Representative graphs are shown from 3 biological replicates





FIG. 9: Cell viability graphs representing PARP inhibitor potentiation of TMZ efficacy in SJ-G2 IDH1wt (A) and SJ-G2 IDH1mt R132H (B) isogenic pairs. Representative graphs are shown, error bars represent +/- SD



**FIG. 10: Anti-tumour efficacy (A) and change in body weight (B) of a U87MG xenograft model dosed with: i) vehicle; ii) Compound 20 alone (3 mg/kg QD); iii) TMZ at a lower dose (6.25 mg/kg QD on days 1-5 and 29-33); iv) TMZ at a higher dose (25 mg/kg QD on days 1-5 and 29-33); and v) the combination of Compound 20 and TMZ at the lower dose**





FIG. 11: Cell confluence graphs representing PARP inhibitor potentiation of VAL-083 efficacy in U87 IDH1wt (A) and U87 IDH1mt R132H (B) isogenic pairs. Representative graphs are shown, error bars represent +/- SD



**FIG. 12: Cell confluence graphs representing PARP inhibitor potentiation of VAL-083 efficacy in SJ-G2 IDH1wt (A) and SJ-G2 IDH1mt R132H (B) isogenic pairs. Representative graphs are shown, error bars represent +/- SD**




FIG. 13 shows cell confluence graph representing PARP inhibitor potentiation of IR efficacy in BT245 H3K27M paediatric gliomas

